$19.25Peak — highest point inside the window, not a realized return
$16.05Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 19 days.
At window close
+1.8%
realized, from the publication price to the last close inside the window
Peak gain
+22.1%
peak, from the publication price — not a realized return
S&P 500, same window
+1.3%
SPY over the identical days, dividend-adjusted
Window close
$16.05
last close inside the window, ended September 1, 2026
Peak price
$19.25
peak on June 24, 2026 — not a realized return
Days to target
19
The thesis — published June 3, 2026
Predicted growth
+8%
over the measurement window
Target price
$17.03
the price the thesis aimed for
Entry zone
$15.00 – $16.00
the fair-value band we waited for
Price at publication
$15.77
published June 3, 2026
Confidence
70%
how strongly the data lined up
Timeframe
Short-term (0–3 months)
Aurinia looks attractive because it is cheap relative to its earnings, has plenty of cash, and potential steady revenue growth. A new public stake by Tang Capital gives a near-term reason investors might pay attention. However, expected near-term gains are modest and biotech news can swing the stock, so confidence is cautious and short-term cases are selective.
Primary drivers
Tang Capital stake creates a visible near-term event
Strong cash position lowers financing risk
Company trades cheaply given its earnings
Biotech headlines can quickly limit upside
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.